There is a moment in every medical press release when the adjective arrives. A therapy is “novel.” A result is “promising.” A platform is “transformative.” Somewhere between the hazard ratio and the headline, a careful scientific claim begins trying on a louder suit. JFK Communications makes its living in that fitting room.
The firm is a small, privately held communications agency founded in Princeton in 2004 by John F. Kouten and David Avitabile. Its clients make drugs, diagnostics, medical devices, tumor-profiling systems, and other products whose stories cannot be separated from evidence, regulation, and human consequence. The agency’s job is to help those stories travel - to reporters, physicians, patients, employees, advocates, and investors - without changing their meaning on the way.
That sounds like public relations because it is. But it is public relations with an unusually crowded fact-checking desk. A product launch may involve a mechanism-of-action video, an online press kit, an advisory-committee meeting, a key opinion leader, a frightened patient, a skeptical trade reporter, and a regulator who cares very much about the precise tense of a verb. JFK sells the ability to keep those characters in the same story.
A family argument becomes a market niche
Kouten grew up listening to a recurring household debate. His father was an orthopedic surgeon. His mother was an operating-room nurse. His grandfather was a pharmaceutical chemist who had helped the FDA develop manufacturing practices. Who healed people - drugs, surgeons, or nurses? His mother, Kouten has said, tended to win.
Kouten was the verbal one. After agency work, he joined Bristol-Myers Squibb and later Johnson & Johnson, working in oncology, HIV, infectious disease, and the anemia drug Procrit. Before JFK existed, he helped connect Bristol-Myers Squibb with cyclist and cancer survivor Lance Armstrong for the Cycle of Hope campaign. The lesson was not merely that celebrity attracts attention. It was that a patient story can turn an abstract treatment category into something a family can picture.
“More than 90 percent of their experiments wind up in nothing.”John F. Kouten, on the scientists behind drug discovery
That observation contains the agency’s real subject. Science advances through disciplined disappointment. Communications often prefers a clean victory. The specialist earns its fee by living inside the mismatch.
The product is a sequence, not a press release
JFK’s service list is broad: product PR, media relations, patient advocacy, data communications, media training, issues management, digital and social strategy, and inbound marketing. The coherence appears when those services are arranged in time.
One clinical fact, five translations
A clinical-trial launch creates one kind of opening. A filing acceptance creates another. An FDA advisory committee creates scrutiny before it creates news. A withdrawal or compliance problem reverses the emotional temperature entirely. JFK explicitly treats these regulatory events as a calendar of opportunities and threats. That is a more precise product than “buzz.” It is choreography.
The public case studies show the choreography at work. For GE Healthcare Medical Diagnostics, the agency says it handled mature brands, product launches and relaunches, pipeline communications, issues, employee communications, and opinion-leader training. For Novartis Oncology, it supported Zometa and Exjade/Asunra across data, meetings, media training, advocacy, and an oncology advisory committee. For Prometheus Laboratories and Proleukin, the work reached patients and physicians through workshops, education, congress support, articles, trade media, and digital channels.
What the disclosed case studies emphasize
The sentence most agencies avoid
On its media-relations page, JFK makes an excellent anti-pitch: “If we do not believe you have news, we will counsel you accordingly.” Seven words of negative space follow the sales promise. No news. Imagine that.
The line exposes the conditions under which this model works. The client must have evidence worth translating. It must be willing to collaborate, permit senior people to learn the technical context, and submit the work to appropriate medical, legal, and regulatory review. If the underlying claim is weak, specialist vocabulary will not rescue it. If the organization wants volume at any cost, counsel becomes decoration.
The business model follows. There are no software seats or off-the-shelf subscription tiers. Clients buy projects and continuing agency-of-record relationships, scoped around teams, deliverables, counsel, vendors, and out-of-pocket costs. That makes JFK an alternative to a large global network on one side and an in-house communications team on the other. Its advantage is senior therapeutic and functional experience without the machinery of a giant agency. Its constraint is the same thing: a boutique depends on the attention of a relatively small bench.
What changed was the channel, not the standard
In 2014, Kouten argued that healthcare communicators needed to leave their “stuffy analog boxes” and combine traditional PR with inbound marketing. The practical shift was from a press release used once to a verified piece of content reused intelligently: a release becomes a landing page, a technical slide becomes a clinician explainer, a video becomes a social clip, and each version produces measurable behavior.
He also advocated “fast-to-fail” communications programs: test tactics, expand the ones that perform, discontinue the ones that do not. The apparent contradiction is useful. Move quickly with format and distribution. Move slowly with claims. The first thing allowed to fail is the tactic, not the truth.
The part worth copying
- Start with the regulatory or clinical milestone, not the content format.
- Write one evidence-backed message before adapting it by audience.
- Give patients context and agency; do not use them as decorative proof.
- Measure channels quickly, then stop funding tactics that do not travel.
- Keep one sentence available for the client: this is not news yet.
That last habit is the moat. Generalist agencies can hire medical writers. Large networks can assemble oncology practices. Internal teams know their molecules better than any outsider. JFK fits where an organization needs an external editor who understands both the science and the room: what a reporter will challenge, what a physician will notice, what a patient will hear, and what a regulator will read twice.
The company now publishes on FDA enforcement, agentic AI in pharma, scientific-paper fraud, the patient journey, and the practical ordeal of the ASCO congress. The topics have expanded. The old family argument remains underneath them. Drugs, doctors, nurses - who gets to explain what healing looks like? JFK Communications has spent two decades answering with a job description: the translator does.